---
title: "UBS lowers the target price of INNOVENT BIO to 124 yuan, reiterating a \"Buy\" rating"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/280746847.md"
description: "UBS has lowered the target price for INNOVENT BIO to 124 yuan, reiterating a \"Buy\" rating. The report indicates that INNOVENT BIO's revenue in the second half of last year was 7.1 billion yuan, an annual increase of 29.6%, with a net loss of 21 million yuan. The total revenue for the year was 13 billion yuan, with a net profit of 814 million yuan, successfully turning a profit. UBS has raised its spending forecast and lowered the earnings per share forecast for this year and next by 52% and 27%, respectively, but maintains its peak sales forecast unchanged"
datetime: "2026-03-27T07:09:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280746847.md)
  - [en](https://longbridge.com/en/news/280746847.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280746847.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/280746847.md) | [繁體中文](https://longbridge.com/zh-HK/news/280746847.md)


# UBS lowers the target price of INNOVENT BIO to 124 yuan, reiterating a "Buy" rating

UBS published a research report indicating that INNOVENT BIO (01801.HK) had a revenue of RMB 7.1 billion in the second half of last year, an annual increase of 29.6%, which met expectations; during this period, the net loss was RMB 21 million, falling short of the bank's and market expectations. The total revenue for the entire year was RMB 13 billion, an annual increase of 38.4%, with a net profit of RMB 814 million, successfully turning a profit.

In addition, INNOVENT BIO maintains its targets of achieving product sales of RMB 20 billion by 2027 and having five candidate drugs enter global Phase III clinical trials by 2030.

UBS has adjusted its expenditure forecast for the company based on INNOVENT BIO's data from the second half of last year, and considering the general commercialization of biopharmaceuticals and the initiation of global Phase III clinical trials, it has lowered its earnings per share forecasts for this year and next by 52% and 27%, respectively, but kept the peak sales forecast unchanged. The target price has been reduced from RMB 131.2 to RMB 124, reiterating a "Buy" rating

### 相关股票

- [INNOVENT BIO (01801.HK)](https://longbridge.com/zh-CN/quote/01801.HK.md)

## 相关资讯与研究

- [Innovent Biologics posts FY profit RMB813.6 million](https://longbridge.com/zh-CN/news/280626112.md)
- [Innovent Bio's Tabosun Gets China Nod as Pre-treatment for Colon Cancer](https://longbridge.com/zh-CN/news/270943961.md)
- [Innovent Biologics Phase 3 STAR Study Shows Efdamrofusp Alfa Effective In NAMD](https://longbridge.com/zh-CN/news/280236866.md)
- [Innovent Biologics' Q4 Revenue Surges 60%](https://longbridge.com/zh-CN/news/274820825.md)
- [Innovent Biologics says FY IFRS revenue rmb13.04 billion](https://longbridge.com/zh-CN/news/280622281.md)